The SimInSitu project has completed its third year and has completed a significant portion of the defined tasks & work-packages and has achieved many milestones. All scaffold materials were fully characterized using a multitude of test modalities. Additionally, the epistemics uncertainty origination from the test methods and process implementation was evaluated via Round Robin test, while the aleatory uncertainty was evaluated by using a statistically adequate number of test samples. Furthermore, crack-growth was assessed experimentally. Relying on these experimental characterization data, complex anisotropic, hyperelastic material models were developed, implemented in commercial Finite Element Method (FEM) software, verified and validated. Using specifically developed Bayesian-statistic based calibration process, all needed material parameters and their distribution functions were evaluated. A separate validation, sensitivity analysis, and uncertainty quantification completed this work. Within the Device-Modelling work-package, two out of three heart-valve devices are completely developed in the Finite Element Method (FEM), Computation Fluid Dynamics (CFD), and Fluid Structure Interaction (FSI) domains. For the FEM-models, Verification, in-vitro Validation, and Uncertainty Quantification were completed successfully. For the CFD domain, one model has completed the verification, in-vitro validation, and QU phase, while the second model is currently in the in-vitro validation, using advanced test methodologies, such as laser-based Particle image velocimetry (PIV). The third device-model is currently in the FEM development phase. In parallel, patient-specific model-libraries were developed for the Transcatheter Aortic Valve Implantation (TAVI) and Right Ventricle Outflow Tract (RVOT) models. 130 patient-specific left-heart models were developed, while the device & FSI implementation and associated verification phase was completed. Currently the clinical validation is ongoing focussing on device deployment (structural) and haemodynamic performance (FSI). For the RVOT side, the patient-specific models are all developed (>25), and a semi-automatic device implementation simulating the surgical placement is completed as well. FSI integration is also completed. After its verification phase, these models will be used for a clinical validation as well. Additionally, the Endogenous Tissue Restauration (ETR) process has been developed, verified, and calibrated in terms of two competing constitutive growth-and-remodelling material models. Several animal trials, which were not always fully successful, were conducted to generate data that was used to calibrate the ETR models. Additionally, historical data from a large collection of animal trial data is provided by a consortium partner, which supports the calibration process. Currently, an advanced sequential modelling process (ETR-FSI) is being developed, which accounts for the impact of a growing tissue on the haemodynamic situation. The in-silico platform work-package has not fully started yet, except for some preparation activities to define an in-silico trial process. Dissemination and Exploitation is picking up momentum with continuous stream of social-media / web-based contributions, a second combined EU workshop (innovaHeart 2024), a collaboration with other related consortia in the EU funded Horizon Results Booster, and additional publications.